GCP
CLDX icon

GSA Capital Partners’s Celldex Therapeutics CLDX Stock Holding History

GSA Capital Partners’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-18,308
Closed -$474K – 1709
2025
Q3 		$474K Buy
+18,308
New +$424K 0.04% 877
2025
Q2 		– Sell
-62,326
Closed -$1.13M – 1784
2025
Q1 		$1.13M Buy
+62,326
New +$1.39M 0.1% 288
2024
Q4 		– Sell
-16,114
Closed -$548K – 1652
2024
Q3 		$548K Buy
16,114
+10,581
+191% +$403K 0.04% 848
2024
Q2 		$205K Sell
5,533
-1,508
-21% -$56.9K 0.01% 1447
2024
Q1 		$296K Buy
+7,041
New +$289K 0.02% 1224
2023
Q4 		– Sell
-44,716
Closed -$1.23M – 1541
2023
Q3 		$1.23M Buy
44,716
+29,404
+192% +$922K 0.11% 298
2023
Q2 		$520K Sell
15,312
-9,630
-39% -$325K 0.05% 708
2023
Q1 		$897K Buy
+24,942
New +$1.08M 0.09% 373
2022
Q4 		– Sell
-11,116
Closed -$312K – 1516
2022
Q3 		$312K Buy
+11,116
New +$341K 0.04% 899
2022
Q1 		– Sell
-18,726
Closed -$724K – 1467
2021
Q4 		$724K Buy
+18,726
New +$816K 0.09% 368
2021
Q3 		– Sell
-9,769
Closed -$327K – 1473
2021
Q2 		$327K Buy
+9,769
New +$268K 0.04% 898
2019
Q1 		– Sell
-52,617
Closed -$156K – 1463
2018
Q4 		$156K Sell
52,617
-32,083
-38% -$158K 0.02% 1155
2018
Q3 		$573K Buy
84,700
+42,047
+99% +$294K 0.03% 1000
2018
Q2 		$322K Buy
+42,653
New +$570K 0.02% 1359
2015
Q3 		– Sell
-6,938
Closed -$2.63M – 1772
2015
Q2 		$2.63M Buy
6,938
+3,254
+88% +$1.29M 0.1% 218
2015
Q1 		$1.54M Buy
+3,684
New +$1.32M 0.06% 522
2014
Q2 		– Sell
-803
Closed -$213K – 1818
2014
Q1 		$213K Sell
803
-1,464
-65% -$561K 0.02% 1344
2013
Q4 		$823K Sell
2,267
-1,366
-38% -$526K 0.07% 485
2013
Q3 		$1.93M Buy
3,633
+12
+0.3% +$4.12K 0.15% 130
2013
Q2 		$848K Buy
+3,621
New +$713K 0.1% 272

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

GSA Capital Partners's CLDX Position: Q4 2025 in Review

GSA Capital Partners sold out of Celldex Therapeutics (CLDX) in Q4 2025, closing a stake of 18,308 shares — an estimated $474K sold.

GSA Capital Partners first reported a position in CLDX in Q2 2013 and held it in 20 quarters. The position peaked at $2.63M in Q2 2015. 185 funds tracked by Wall St. Rank hold CLDX as of Q4 2025.

  • GSA Capital Partners reported no remaining Celldex Therapeutics position as of Q4 2025 after selling out during the quarter.
  • GSA Capital Partners sold 18,308 Celldex Therapeutics shares in Q4 2025, an estimated $474K.
  • GSA Capital Partners first reported a position in Celldex Therapeutics in Q2 2013 and held it in 20 quarters.
  • GSA Capital Partners's Celldex Therapeutics position peaked at $2.63M in Q2 2015.
  • 185 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q4 2025.

Based on GSA Capital Partners's 13F filing for Q4 2025, filed 6 Feb 2026.